FDA Approves Tucatinib for HER2-Positive Metastatic Breast Cancer Maintenance Treatment

The U.S. Food and Drug Administration (FDA) has approved tucatinib (Tukysa), in combination with trastuzumab and pertuzumab, for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. This regulatory action provides a new option for patients in this setting.